Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease

Cancer Journal from Scientific American

Volumn 5, Issue 5, 1999, Pages 275-282

  Viviani, Simonetta ^a   Bonfante, Valeria ^a   Santoro, Armando ^a   Zanini, Marcello ^a   Devizzi, Liliana ^a   Di Russo, Anna ^a   Soncini, Fulvia ^a   Villani, Fabrizio ^a   Ragni, Guido ^b   Valagussa, Pinuccia ^a   Bonadonna, Gianni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Advanced stage; Chemotherapy; Hodgkin's disease; Involved field radiotherapy

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CARDIOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MALE; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032841522     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Levi F, La Vecchia C, Lucchini F et al. Mortality from Hodgkin's disease and other lymphomas in Europe, 1960-1990. Oncology 1995;52:93-96.
2. Bonadonna G, Valagussa P. The influence of clinical trials on current treatment strategy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1990;19:209-218.
3. Canellos GB, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
4. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:1421-1430.
5. Bonadonna G, Santoro A, Gianni AM et al. Clinical evaluation of non - cross-resistant therapies in advanced Hodgkin's disease. In: Tsuruo T, Ogawa M, eds. Drug Resistance as a Biochemical Target in Cancer Chemotherapy. San Diego: Academic Press, 1992: 271-293.
6. Coldman A, Goldie JH. Impact of dose-intensive chemotherapy on the development of permanent drug resistance. Semin Oncol 1987;4[suppl 4]:29-33.
7. Carde P, Mackintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983;1:146-153.
8. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306.
9. Rijswijk RZN, vanHaahen C, Dekker AW et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989;7:1776-1782.
10. DeVita VT, Hubbard SM, Longo DL. Treatment of Hodgkin's disease. J Natl Cancer Inst Monographs 1990;10:19-28.
11. Taylor ME, McElvain TJ, Bannet A et al. Etoposide as a single agent in advanced relapsed lymphomas: a phase II study. Cancer Chemother Pharmacol 1982;7:175-177.
12. Bonadonna G, Gianni L, Santoro A et al. Drugs ten years later: epirubicin. Ann Oncol 1993;4:359-369.
13. Viviani S, Santoro A, Ragni G et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985;21:601-605.
14. Anselmo AP, Cartoni C, Bellantuono P et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990;75:155-158.
15. Henry-Amar M, Dietrich PY. Acute leukemia after treatment of Hodgkin's disease. Hematol Oncol Clin North Am 1993;7:369-387.
16. Haynes RC. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and action of adenocortical. In: Goodman GA, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990:1431-1462.
17. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. Costwolds Meeting. J Clin Oncol 1989;7: 1630-1636.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [B] 1972;34:187-220.
20. Miller RC. Survival Analysis. New York: John Wiley & Sons, 1981.
21. Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-1687.
22. Winick NJ, McKenna RW, Shuster JJ et al. Secondary myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993;11:209-217.
23. Valagussa P, Bonadonna G. Carcinogenic effect of cancer treatment. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press, 1995:2348-2358.
24. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 1996;7(S4):95-98.
25. Diehl V: Dose-escalation study for treatment of Hodgkin's disease. The German Hodgkin Study Group. Ann Hematol 1993; 66:139-140.
26. Hill M, Milan S, Cunningham D et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995;13:387-395.
27. Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 1996;7[suppl 4]:105-108.
28. Diehl V, Franklin J, Hasenclever D et al. BEACOPP: a new dose-escalated and accelerated regimen, is at least as effective as COPP/ ABVD in patients with advanced-stage Hodgkin's lymphoma. Interim Report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998;16:3810-3821.
29. Pavlovsky S, Santarelli MT, Sackmann FM et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A e B Hodgkin's disease. Ann Oncol 1992;3:533-537.
30. Bonadonna G. Modern treatment of malignant lymphomas: a multidisciplinary approach? Ann Oncol 1994;5[suppl 2]:505-516.
31. Hoppe RT. Hodgkin's disease: the role of radiation therapy in advanced disease. Ann Oncol 1996;7[suppl 4]:5099-5103.
32. Raemaekers Y, Burges M, Henry-Amar H et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial. Ann Oncol 1997;8[suppl 1]: 5111-5114.
33. Reece DE, Phillips GL. Intensive therapy and autotransplantation in Hodgkin's disease. Stem Cells 1994;12:477-493.
34. Yuen AR, Rosenberg SA, Hoppe RT. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814-822.
35. Fisher RI, De Vita VT, Hubbard SP et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979;90:761-763.
36. Viviani S, Santoro A, Negretti E et al. Salvage chemotherapy in Hodgkin's disease: results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990;1:123-127.
37. Longo DL, Duffley PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability of cure. J Clin Oncol 1992;10:210-218.
38. Salvagno L, Sorarù M, Aversa SML et al. Late relapse in Hodgkin's disease: outcome of patients relapsing more than twelve months after primary chemotherapy. Ann Oncol 1993;4:657-662.
39. Bonfante V, Santoro A, Devizzi L et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997;15:528-534.
40. Benyunes M, Fefer A Interleukin-2 in the treatment of hematologic malignancies. In: Atkins M, Mier J, eds. Therapeutic Application of Interleukin-2. New York: Marcel Dekker, 1993:163-175.
41. Nichols J, Foss F, Kuzel TM et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997;23[suppl 1]:534-536.
42. Winkler U, Barth S, Schnell R et al. The emerging role of immunotoxins in leukemia and lymphoma. Ann Oncol 1997;8[suppl 1]: 139-146.
43. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996;14:1383-1400.